Equillium to Present at Investor Conferences in November 2018
LA JOLLA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that Bruce Steel, Equillium’s President and Chief Business Officer, will present at two upcoming investor conferences in November 2018.
|
Event: Date: Time: Location: |
Stifel 2018 Healthcare Conference Tuesday, Nov. 13, 2018 5:00 p.m. ET New York, NY |
|
|
Event: Date: Time: Location: |
Jefferies 2018 London Healthcare Conference Thursday, Nov. 15, 2018 8:00 a.m. GMT London, United Kingdom |
|
Live webcasts of both presentations will be available under the Investors section of the Company’s website at https://ir.equilliumbio.com/. Replays will be available for 30 days following each webcast.
About Equillium
Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic. For more information, visit www.equilliumbio.com.
Investor Contact
Tim McCarthy
LifeSci Advisors, LLC
+1-212-915-2564
tim@lifesciadvisors.com
Media Contact
Heidi Chokeir, Ph.D.
Canale Communications
+1-619-203-5391
heidi@canalecomm.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
